Your browser doesn't support javascript.
loading
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial.
Barbour, A P; Walpole, E T; Mai, G T; Barnes, E H; Watson, D I; Ackland, S P; Martin, J M; Burge, M; Finch, R; Karapetis, C S; Shannon, J; Nott, L M; Varma, S; Marx, G; Falk, G L; Gebski, V; Oostendorp, M; Wilson, K; Thomas, J; Lampe, G; Zalcberg, J R; Simes, J; Smithers, B M.
Afiliación
  • Barbour AP; Divisions of Surgery and Cancer Services, Princess Alexandra Hospital, Brisbane, Australia; Faculty of Medicine, The University of Queensland, Brisbane, Australia. Electronic address: a.barbour@uq.edu.au.
  • Walpole ET; Divisions of Surgery and Cancer Services, Princess Alexandra Hospital, Brisbane, Australia.
  • Mai GT; Divisions of Surgery and Cancer Services, Princess Alexandra Hospital, Brisbane, Australia.
  • Barnes EH; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Watson DI; Department of Surgery, Flinders Medical Centre, Adelaide, Australia; School of Medicine, Flinders University, Adelaide, Australia.
  • Ackland SP; School of Medicine and Public Health, University of Newcastle, Newcastle, Australia.
  • Martin JM; School of Medicine and Public Health, University of Newcastle, Newcastle, Australia.
  • Burge M; Faculty of Medicine, The University of Queensland, Brisbane, Australia; Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia.
  • Finch R; Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia.
  • Karapetis CS; Department of Surgery, Flinders Medical Centre, Adelaide, Australia; School of Medicine, Flinders University, Adelaide, Australia.
  • Shannon J; Nepean Cancer Centre, Nepean Hospital, Sydney, Australia.
  • Nott LM; Medical Oncology, Royal Hobart Hospital, Hobart, Australia.
  • Varma S; Cancer Services, Townsville Hospital, Townsville, Australia.
  • Marx G; Clinical Trials Unit, Sydney Adventist Hospital, Sydney, Australia.
  • Falk GL; Clinical Trials Unit, Sydney Adventist Hospital, Sydney, Australia.
  • Gebski V; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Oostendorp M; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Wilson K; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Thomas J; Divisions of Surgery and Cancer Services, Princess Alexandra Hospital, Brisbane, Australia; Clinical Trials, Mater Research Institute, Brisbane, Australia.
  • Lampe G; Divisions of Surgery and Cancer Services, Princess Alexandra Hospital, Brisbane, Australia.
  • Zalcberg JR; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
  • Simes J; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Smithers BM; Divisions of Surgery and Cancer Services, Princess Alexandra Hospital, Brisbane, Australia; Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Ann Oncol ; 31(2): 236-245, 2020 02.
Article en En | MEDLINE | ID: mdl-31959340

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Adenocarcinoma Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Adenocarcinoma Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article